Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
PHASE3
The safety and efficacy of pembrolizumab plus the investigator's choice of ...
Status
Active Not Recruiting
Location
University of Alabama at Birmingham-Medicine ( Site 0065)
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study
PHASE3
The purpose of the China Extension study is to assess the safety and effica...
Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
PHASE3
This is a study to assess the efficacy and safety of pembrolizumab (MK-3475...
Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
PHASE3
The purpose of this study is to determine the efficacy and safety of pembro...
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
PHASE1
Substudy 02B is part of a larger research study where researchers are looki...
Status
Completed
Location
The Angeles Clinic and Research Institute ( Site 2009)
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)
PHASE2
The purpose of this study is to assess the efficacy and safety of pembroliz...